{"organizations": [], "uuid": "e2ff2670acde6851599ed9ef79ead59b3904fdbf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-revance-therapeutics-inc-announced/brief-revance-therapeutics-inc-announced-interim-8-week-phase-2a-results-for-rt002-in-treating-plantar-fasciitis-idUSFWN1P30LN", "country": "US", "domain_rank": 408, "title": "BRIEF-Revance Therapeutics Inc Announced Interim 8-Week Phase 2A Results For Rt002 In Treating Plantar Fasciitis", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.427, "site_type": "news", "published": "2018-01-08T21:21:00.000+02:00", "replies_count": 0, "uuid": "e2ff2670acde6851599ed9ef79ead59b3904fdbf"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-revance-therapeutics-inc-announced/brief-revance-therapeutics-inc-announced-interim-8-week-phase-2a-results-for-rt002-in-treating-plantar-fasciitis-idUSFWN1P30LN", "ord_in_thread": 0, "title": "BRIEF-Revance Therapeutics Inc Announced Interim 8-Week Phase 2A Results For Rt002 In Treating Plantar Fasciitis", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "revance therapeutics inc", "sentiment": "negative"}, {"name": "brief-revance therapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Revance Therapeutics Inc:\n* REVANCE THERAPEUTICS INC - ANNOUNCED INTERIM 8-WEEK PHASE 2A RESULTS FOR RT002 IN TREATING PLANTAR FASCIITIS\n* REVANCE THERAPEUTICS INC - TRIAL‘S PRIMARY ENDPOINT SHOWED ROBUST IMPACT ON PAIN, WITH GREATER THAN 50% REDUCTION FOR PATIENTS TREATED WITH RT002\n* REVANCE THERAPEUTICS INC - RT002 APPEARED TO BE GENERALLY SAFE AND WELL-TOLERATED THROUGH WEEK 8\n* REVANCE THERAPEUTICS - EXPECT TO CONDUCT ANOTHER PHASE 2A TRIAL WITH MODIFIED DESIGN TO DEMONSTRATE RT002‘S ABILITY TO TREAT PLANTAR FASCIITIS Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T21:21:00.000+02:00", "crawled": "2018-01-09T17:03:15.036+02:00", "highlightTitle": ""}